Bicycle Therapeutics (BCYC) Free Cash Flow (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Free Cash Flow came in at -$49.9 million in Q2 2026, up 31.95% YoY from -$37.8 million in Q2 2025, and up 25.16% on a QoQ basis from -$66.6 million in Q1 2026.
Bicycle Therapeutics (BCYC) Free Cash Flow (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Free Cash Flow data on file, last reported at -$49.9 million in Q2 2026.
- Quarterly Free Cash Flow rose 31.95% year-over-year to -$49.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$208.3 million (up 0.96% YoY) and the FY2025 annual result came in at -$252.0 million, down 51.86% from the prior year.
- Free Cash Flow rose to -$49.9 million in Q2 2026, from -$66.6 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $33.8 million in Q2 2023 to a low of -$87.0 million in Q1 2025.
- A 5-year average of -$39.1 million and a median of -$42.7 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow soared 201.47% — and 2024, when it plunged 2537.0%.
- Tracing BCYC's Free Cash Flow over 5 years: stood at -$31.8 million in 2022, then tumbled by 49.07% to -$47.3 million in 2023, then jumped by 79.37% to -$9.8 million in 2024, then sank by 104.01% to -$19.9 million in 2025, then tumbled by 150.36% to -$49.9 million in 2026.
- The last three Free Cash Flow figures came in at -$49.9 million (Q2 2026), -$66.6 million (Q1 2026), and -$19.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | -49.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -49.87 Mn |
| Jun 30, 2026 | -49.87 Mn |
| Mar 31, 2026 | -66.64 Mn |
| Mar 31, 2026 | -66.64 Mn |
| Dec 31, 2025 | -19.92 Mn |
| Dec 31, 2025 | -19.92 Mn |
| Sep 30, 2025 | -71.85 Mn |
| Sep 30, 2025 | -71.85 Mn |
| Jun 30, 2025 | -73.28 Mn |
| Jun 30, 2025 | -73.28 Mn |
| Mar 31, 2025 | -86.97 Mn |
| Mar 31, 2025 | -86.97 Mn |
| Dec 31, 2024 | -9.76 Mn |
| Dec 31, 2024 | -9.76 Mn |
| Sep 30, 2024 | -40.27 Mn |
| Sep 30, 2024 | -40.27 Mn |
| Jun 30, 2024 | -45.05 Mn |
| Jun 30, 2024 | -45.05 Mn |
| Mar 31, 2024 | -70.88 Mn |
| Mar 31, 2024 | -70.88 Mn |